Posted On: 03/11/2015 9:56:47 AM
Post# of 7769
This conference is another opportunity for Mr. Schneiderman to grow the awareness of SCRC to the investment world. Remember what happened after the SeeThruEquity conference? The same thing will occur here as well. The difference is the SCRC has more chapters included in it's book of success beyond compounding. PIMD is starting to show significant revenue growth, the Diabetes Program is "humming", and I am sure Mr. Schneiderman will discuss the implementation of the propsed Physician Dispensing program. Yes, I bet he will also discuss RapiMeds and potential this will add to the bottom line.
As an FYI, an article in the business section today stated ExpressScripts reported a 31% increase for specialty pharmacy drugs in 2014 compared to a 6.4% increase for traditional pharmaceuticals. What does this tell you? It tells you Physicians and Patients realize the benefits of specialty drugs vs the traditional therapies. These specialty drugs are more effective and safer than oral medications which could present debilitating side effects. Insurance carriers and PBM may be able to impact the reimbursement amounts but they will not be able to put an end to compounding pharmacy. As longs as Mr. Schneiderman continues to add more pharmacies to SCRC, like he is doing, our revenues will rebound and exceed the numbers from 2014.
As an FYI, an article in the business section today stated ExpressScripts reported a 31% increase for specialty pharmacy drugs in 2014 compared to a 6.4% increase for traditional pharmaceuticals. What does this tell you? It tells you Physicians and Patients realize the benefits of specialty drugs vs the traditional therapies. These specialty drugs are more effective and safer than oral medications which could present debilitating side effects. Insurance carriers and PBM may be able to impact the reimbursement amounts but they will not be able to put an end to compounding pharmacy. As longs as Mr. Schneiderman continues to add more pharmacies to SCRC, like he is doing, our revenues will rebound and exceed the numbers from 2014.
(0)
(0)Scroll down for more posts ▼
